Meet with Johnson & Johnson oncology leaders

Application due by June 10th - In-person meeting on July 6th.

Cancer remains one of the most pressing global health challenges and Johnson & Johnson is committed to changing it.

We are advancing transformative innovations in lung, head and neck, and other cancers, and accelerating the development of breakthrough therapies that make a real difference. Our strategy is rooted in understanding the biological complexity of cancer to develop novel therapies tailored to distinct disease subgroups, leveraging our deep expertise across modalities such as small molecules, multi-specific antibodies, antibody-drug conjugates, cell therapies, and other cutting-edge platforms.

Johnson & Johnson is also focused on building external partnerships to further advance therapeutic solutions for cancer. Thus, we are inviting visionary startups and researchers to connect with our oncology team and explore opportunities in:

• Lung cancer (small cell and non-small cell, including squamous and adenocarcinoma)
• Head and neck cancers
• Bladder, prostate, or hematologic malignancies
• Interventional oncology solutions, including controlled release, localized depot drug delivery, and integrated platforms for delivering, monitoring, and confirming intra-tumoral therapies

If you are developing bold, differentiated, and potentially transformative therapeutic approaches in these areas, we would like to hear from you. Selected applicants will be invited to present their projects directly to Johnson & Johnson’s oncology leaders.

Meet with J&J oncology leaders—apply to present your bold oncology innovation and explore partnering.

Application due by: June 10th.
Selected companies will be notified by June 19th.
In-person meeting on July 6th. Details to be coordinated with each selected company.